GenMark Diagnostics, Inc. (GNMK)

Check out top investors' recommendation for GNMK
Last closing price (Oct 01 4:00 EDT):
8.99 (0.22%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
-33.85% ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company’s products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. It also offers 8 diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, which detects a panel of mutations associated with cystic fibrosis; Warfarin Sensitivity test that determines an individual’s ability to metabolize the oral anticoagulant warfarin; Thrombophilia Risk Test, which detects an individual’s increased risk of blood clots; and Respiratory Viral Panel test that simultaneously detects and differentiates 14 clinically relevant viruses from patients with influenza-like illnesses. The company’s diagnostic tests also include Hepatitis C Virus Genotyping test for the detection and typing/subtyping of HCV; 3A4/3A5 Genotyping test designed for the detection and genotyping of the alleles of the CYP450 3A4 gene locus and CYP450 3A5 gene locus; and 2C19 Genotyping test for the detection and genotyping alleles of the cytochrome P450 (CYP450) 2C19 gene locus. In addition, the company engages in developing a NexGen system to integrate automated nucleic acid extraction and amplification with its eSensor detection technology to enable technicians to place a patient sample into test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Jeffrey Frelick Canaccord Genuity Buy   Aug 08, '13   9.69  14.00  Aug 08, '14  44.48% 
Jeffrey Frelick Canaccord Genuity Buy   Apr 14, '13   13.62  18.00  Apr 14, '14  -30.47% 
Jeffrey Frelick Canaccord Genuity Buy   Jan 14, '13   11.14  14.00  Jan 14, '14  25.67% 
William Quirk Piper Jaffray Buy   Mar 03, '11   4.44  8.00  Mar 03, '12  -6.53% 
Jeffrey Frelick Canaccord Genuity Buy   Feb 10, '11   4.42  8.00  Feb 10, '12  -0.68%